Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  KOREA EXCHANGE  >  Celltrion, Inc.    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report  
 SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (KRW)
Sales 2019 1 108 B
EBIT 2019 403 B
Net income 2019 327 B
Finance 2019 211 B
Yield 2019 0,01%
Sales 2020 1 432 B
EBIT 2020 574 B
Net income 2020 483 B
Finance 2020 462 B
Yield 2020 0,02%
P/E ratio 2019 66,0x
P/E ratio 2020 45,4x
EV / Sales2019 19 474x
EV / Sales2020 15 070x
Capitalization 21 584 B
More Financials
Company
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as... 
More about the company
Surperformance© ratings of Celltrion, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on CELLTRION, INC.
09/03CELLTRION : and Lonza Sign Contract to Manufacture Remsima Drug Substance
AQ
09/03Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
RE
06/27VEEVA : Celltrion Adopts Veeva Vault eTMF for Greater Visibility into Trial Acti..
AQ
04/17CELLTRION : unveils P2 trial results for influenza antibody therapy
AQ
04/16CELLTRION : Diverging from US, Canada Approves Biosimilar Rituximab in Both Onco..
AQ
04/10CELLTRION : and iProgen Biotech announce partnership for development of novel AD..
AQ
04/07CELLTRION : Partners with the Canadian Biotech Company, iProgen Biotech to Devel..
BU
04/05CELLTRION : Completes Enrollment of Phase 3 Trial of CT-P17, Gives Update on Sub..
AQ
03/26CELLTRION : licenses out hypertrophic cardiomyopathy treatment to Japan
AQ
03/08CELLTRION : Healthcare wins biosimilar deals in Singapore and Thailand
AQ
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Sector news : Biotechnology & Medical Research - NEC
02:48aA Plan to Fight Hep C -- WSJ
DJ
09/03Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
RE
08/29GLOBAL MARKETS LIVE : Dell, United Airlines, UBS, Apple…
08/28U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight
RE
08/28US Judge Mostly Sets Aside Jury Ruling on Repatha Patents -Reuters
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 211 904,76  KRW
Last Close Price 169 000,00  KRW
Spread / Highest target 65,7%
Spread / Average Target 25,4%
Spread / Lowest Target -34,9%
EPS Revisions
Managers
NameTitle
Wu-Sung Ki Co-Chief Executive Officer & Director
Hyung-Ki Kim Co-Chief Executive Officer & Director
Myung-Geun Oh Vice President & Operations Manager
Jung-Jin Seo Director
Dong-Il Kim Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.18 337
IQVIA HOLDINGS INC30.28%29 649
LONZA GROUP32.78%25 385
INCYTE CORPORATION20.19%16 438
EXACT SCIENCES CORPORATION69.11%13 817
SEATTLE GENETICS, INC.24.66%11 927